Dyadic International, Inc. (DYAI)

Recent Quarterly Results

Source: Company filings

Price Chart

Dyadic International, Inc. (DYAI) stock price: $0.80 (+0.00, +0.00%)

Why Bull

• •Recent insider buying suggests confidence in Dyadic's future prospects, aligning interests with shareholders.
• •The community is buzzing about potential partnerships leveraging Dyadic's C1 platform for novel applications.
• •Positive sentiment indicates the market is receptive to Dyadic's focus on sustainable protein production.
• •The narrative around biotech innovation is strong, potentially benefiting companies like Dyadic.

Why Bear

• •Lack of concrete partnership announcements leaves some investors skeptical about immediate revenue generation.
• •Community concerns linger regarding the scalability of Dyadic's technology to meet large-scale demand.
• •Market perception may be influenced by broader economic uncertainty impacting smaller biotech companies.
• •Bearish sentiment stems from the long development timelines inherent in the biotech industry, requiring patience.

• Dyadic Applied Biosolutions Announces Commercial Launch Of AlbuFree DX, rHA Product Produced Using Dyadic's Proprietary Filamentous Fungal Expression Technology
  benzinga · Feb 17, 2026
• Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
  Yahoo! Finance: DYAI News · Feb 17, 2026
• Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
  GlobeNewswire · Feb 17, 2026
• Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
  globenewswire.com · Feb 17, 2026

Rationale

AI-generated technical analysis for DYAI including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for Dyadic International, Inc. (DYAI), choose a timeframe, and track your prediction accuracy.

Current price: $0.80

Score Factors

• Revenue Growth 6/100

  Revenue increased 20.6% YoY, reflecting moderate but steady business growth.

• Gross Margin 6/100

  Gross margin of 31.5% is acceptable but leaves limited room for R&D and marketing investment.

• Operating Leverage 6/100

  Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates DYAI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does Dyadic International, Inc. do?

Dyadic International is a biotechnology company that specializes in the development and production of enzymes and other proteins using its patented C1 platform. This platform enables the efficient and cost-effective manufacturing of biologics, including vaccines and therapeutic proteins. The company focuses on developing solutions for both human and animal health, with its lead product candidate, DYAI-100, being a SARS-CoV-2-RBD antigen vaccine. Dyadic aims to partner with pharmaceutical companies and research institutions to commercialize its products and expand the reach of its C1 platform.

Is DYAI stock a good buy?

DYAI stock presents a speculative investment opportunity with high potential upside and significant risks. The company's C1 platform offers a unique value proposition in the biologics manufacturing space, but its success depends on the successful completion of clinical trials and commercialization of its products. With a market capitalization of $0.03 billion and negative P/E ratio of -4.00, DYAI is a high-risk, high-reward investment. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in DYAI.

What are the main risks for DYAI?

The main risks for Dyadic International include the potential for clinical trial failures, competition from established biotechnology companies, regulatory hurdles, and limited financial resources. The company's success depends on the successful development and commercialization of its products, which is subject to significant regulatory and clinical risks. Additionally, Dyadic faces competition from larger and more established biotechnology companies with greater financial resources. The company's limited financial resources also pose a risk to its ability to fund its research and development activities.

Is DYAI a good stock to buy?

Whether DYAI is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the DYAI MoonshotScore?

The MoonshotScore for DYAI is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is DYAI data updated?

DYAI stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to DYAI is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for DYAI?

Growth catalysts for Dyadic International, Inc. (DYAI) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Dyadic International, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are DYAI's main competitors?

Dyadic International, Inc. (DYAI) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether DYAI has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about DYAI?

Wall Street analyst coverage for DYAI includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is DYAI's market cap?

Market capitalization (market cap) for DYAI is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows DYAI's current market cap alongside enterprise value and other valuation metrics.

How has DYAI stock performed recently?

DYAI's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing DYAI's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in DYAI?

Key risk categories for DYAI include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures DYAI's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling DYAI?

Insider trading activity for DYAI tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is DYAI a good stock for beginners?

Dyadic International, Inc. (DYAI) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is DYAI for first-time investors?

Every stock carries risk, including Dyadic International, Inc. (DYAI). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like DYAI.